Künstliche Intelligenz in der Pneumologie
Potenzial der Künstlichen Intelligenz in der Rehabilitation
M. Spielmanns
Price
42.00 $
Jahrgang 52 (2026) p. 426 - 430
Abstract
Atemwegs- und Lungenkrankheiten, Jahrgang 52, Nr. 9/2026, S. 426-430
Potenzial der Künstlichen Intelligenz in der Rehabilitation
M. Spielmanns1#2
1Valens, Rehaklinik Wald und Bad Ragaz, Schweiz, 2Universität Witten-Herdecke, Lehrstuhl für Pneumologie, Witten
Künstliche Intelligenz (KI) bietet vielfältige Anwendungsmöglichkeiten in der Rehabilitation, von präziseren Diagnosen und individuellen Behandlungsplänen über unterstützende Therapietools bis hin zum Monitoring- und Motivationsförderung. Durch die Verarbeitung großer Datensätze, Bildgebungs- und Sensorikdaten sowie fortschrittliche Mustererkennung kann KI die Effizienz, Personalisierung und Nachhaltigkeit rehabilitativer Maßnahmen verbessern. Hürden bleiben in Bezug auf Evidenzbasis, Datenschutz, Interoperabilität und ethische Fragestellungen. Zukünftige Forschung sollte robuste Studien, klinische Validierung, multifaktorielle Ansätze und interdisziplinäre Implementierung fokussieren.Correspondence to:
Prof. Dr. med. Marc Spielmanns
Rehaklinik Wald
Faltigbergstrasse 7
8636 Wald, Schweiz
Email: [email protected]
Jahrgang 52 (2026) p. 431 - 432
Abstract
Atemwegs- und Lungenkrankheiten, Jahrgang 52, Nr. 9/2026, S. 431-432
Industrienachricht
Letter
Stevens-Johnson syndrome in toddlers: Treatment and prevention using antivirals and vitamin D3
Andjelka Stojkovic, Katerina Dajic, Andrijana Kostic, Katarina Cukovic Prokic, and Jelena Balovic
p. 0 - 2
Abstract
Andjelka Stojkovic1,2, Katerina Dajic1,2, Andrijana Kostic1,2, Katarina Cukovic Prokic2, and Jelena Balovic2
1Faculty of Medical Sciences, University of Kragujevac, and 2University Clinical Center Clinic of Pediatrics, Kragujevac, Serbia
Correspondence to:
Prof. Andjelka Stojkovic, PhD, MD, Department of Pediatrics, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovic 69, 34000 Kragujevac, Serbia
Email: [email protected]
Original
Analytical validation of an ELISA-based test kit for polymeric IgA immune complexes in IgA nephropathy
Wei Wang, Qi Bian, Qing Zhong, Shasha Chen, Lisha Ma, Zhiyong Guo, Aibing Rao, Jicheng Lv, Hong Zhang, Xingfang Xie, Jing Jin, and Guisen Li
Price
42.00 $
p. 0 - 8
Abstract
Wei Wang1, Qi Bian3, Qing Zhong1,2, Shasha Chen1, Lisha Ma1, Zhiyong Guo3, Aibing Rao4, Jicheng Lv5, Hong Zhang5, Xingfang Xie6, Jing Jin7, and Guisen Li1
1Renal Division and Institute of Nephrology, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, 2Department of Nephrology, Chongzhou People’s Hospital, Sichuan, 3Department of Nephrology, Changhai Hospital, Naval Medical University, Shanghai, 4Shenzhen Luwei (Biomanifold) Biotechnology Limited, Shenzhen, 5Renal Division, Peking University First Hospital Peking University Institute of Nephrology Key Laboratory of Renal Disease, Ministry of Health of China Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Research Units of Diagnosis and Treatment of Immune-mediate Kidney Disease, Chinese Academy of Medical Sciences, Beijing, 6Department of Nephrology, The First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, PR China, and 7Department of Medicine/Nephrology and Hypertension, Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg, School of Medicine, Chicago, IL, USA
Background and objectives: Circulating polymeric IgA immune complexes (Poly-IgA) have been proposed as potential biomarkers for IgA nephropathy (IgAN); however, standardized clinical assays for their detection are not yet available. We developed and analytically validated an ELISA-based test kit for Poly-IgA and evaluated its diagnostic performance in a retrospective, two-center cohort. Materials and methods: Analytical validation of the ELISA kit was performed using samples collected from two independent centers. The validation included evaluation of the linear range, precision, and limit of detection (LOD). Clinical samples comprised healthy controls, patients with IgA nephropathy (IgAN), and patients with non-IgAN kidney diseases (nKD), including membranous nephropathy (MN), focal segmental glomerulosclerosis (FSGS), and other biopsy-confirmed glomerular diseases. Diagnostic sensitivity, specificity, and correlations with routine clinical parameters were evaluated. Results: The test kit demonstrated robust analytical performance, with a limit of blank (LOB) of 10 U/mL, recovery ranging from 85 to 105%, and a linear range of 15.63 – 500 U/mL. Receiver operating characteristic (ROC) curve analysis of retrospective clinical samples yielded an area under the curve (AUC) of 0.87. At an optimal cutoff value of 75.6 U/mL, the assay demonstrated a sensitivity of 82.7%, specificity of 76.0%, and overall diagnostic accuracy of 78.0%. These findings suggest that the assay may serve as a promising diagnostic tool for differentiating IgAN from non-IgAN kidney diseases; however, further validation in larger, multicenter, and more diverse cohorts is warranted. Conclusion: The ELISA-based Poly-IgA test kit was analytically validated and demonstrated good diagnostic performance in differentiating IgAN from nKD in a two-center cohort. Although its specificity of 76% is insufficient to replace kidney biopsy as the diagnostic gold standard, the assay may serve as a promising non-invasive adjunctive tool to support clinical decision-making, particularly for screening and disease monitoring. In light of these limitations, including the relatively small sample size, prospective multicenter studies in larger and more diverse populations are warranted to further establish its clinical utility.
Correspondence to:
Zhiyong Guo, MD, PhD, Department of Nephrology, Changhai Hospital, Naval Medical University, Shanghai, China; or Guisen Li, MD, PhD, Renal Division and Institute of Nephrology, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan, China,
Email: [email protected]
Guideline
S2k-Guideline – Standardized application of the nasal and conjunctival provocation test on allergic diseases of the upper airways
Ulrike Förster-Ruhrmann, Tobias Ankermann, Sven Becker, Petra Bubel, Mandy Cuevas, Moritz Gröger, Ludger Klimek, Lars Lange, Katrin Milger, Philip Maier, Norbert Muelleneisen, Dennis Nowak, Heidi Olze, Uwe Pleyer, Wolfgang Schlenter, Sebastian Schmidt, Antje Schuster, Martin Wagenmann, Bettina Wedi, and Oliver Pfaar
Volume 10 (2026) p. 234 - 258
Abstract
Allergologie select, Vol. 10/2026 (234-258)
S2k-Guideline – Standardized application of the nasal and conjunctival provocation test on allergic diseases of the upper airways
Ulrike Förster-Ruhrmann1, Tobias Ankermann2, Sven Becker3, Petra Bubel4, Mandy Cuevas5, Moritz Gröger6,7, Ludger Klimek8, Lars Lange9, Katrin Milger10,11, Philip Maier12, Norbert Muelleneisen13, Dennis Nowak14, Heidi Olze1, Uwe Pleyer15, Wolfgang Schlenter16, Sebastian Schmidt17, Antje Schuster18, Martin Wagenmann19, Bettina Wedi20, and Oliver Pfaar21
1Department of Otorhinolaryngology, CCM and CVK, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin, Berlin, 2Childrens Hospital, Städtisches Krankenhaus Kiel gGmbH, Kiel, 3Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center, Tübingen, 4ENT practice Dr. Bubel, Eisleben, 5Faculty of Medicine and University Hospital Carl Gustav Carus, Department of Otorhinolaryngology Head and Neck Surgery, TUD Dresden University of Technology, Dresden, 6Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, 7HNO am Maximiliansplatz, Munich, 8Center for Rhinology and Allergology, Wiesbaden, 9Department of Pediatrics, GFO-Kliniken Bonn, St. Marien-Hospital, Bonn, 10Department of Medicine V, University Hospital of the Ludwig Maximilian University Munich, Munich, Germany, 11Division of Respiratory Medicine, Department of Internal Medicine, Medical University of Graz, Austria, 12Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, 13Asthma-Allergiezentrum, Leverkusen, 14Institute and Clinic for Occupational, Social and Environmental Medicine, CPC (Comprehensive Pneumology Center) Munich, DZL, German Center for Lung Research, Munich, 15Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin, 16Langenselbold, 17Department of Pediatrics, University Medicine, Greifswald, 18Center for Paediatric and Adolescent Medicine, University Medical Center, Düsseldorf, 19Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, 20Department of Dermatology and Allergy, Comprehensive Allergy Center, Hanover Medical School, Hannover, and 21Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany
Broad evidence confirms that AR (ICD J30.3) is a chronic disease with high prevalence among children and adults worldwide. Its consequences, both from a public health perspective and at the level of the individual patient, are often underestimated, and the condition is inadequately treated. In addition, AR is often related to comorbidities with additional impact on diseases-severity. Allergen provocation of the easily accessible nasal (nasal allergen provocation test: NPT) or conjunctival mucosa (conjunctival allergen provocation test: CPT) reproduces the allergen-dependent, IgE-mediated allergic reaction under controlled and standardized conditions. These measures are regarded as the diagnostic gold standard, particularly in cases of unclear results in primary allergological tests, enabling clinically relevant identification of the causative allergen. Approved test allergens are critical for ensuring the methodological quality of the NPT. However, their availability is increasingly limited, although adequate quantities of allergen solutions remain indispensable for high-quality nasal allergen testing. Unilateral allergen provocation has been established in the clinical routine for decades in Germany. However, scientific evidence for unilateral application of the test allergen is pending. International position papers differ from this recommendation. The CPT is a simple, safe, and well-tolerated measure. It is primarily used in perennial and, in selected cases, seasonal allergic conjunctivitis. This method is less commonly applied for vernal keratoconjunctivitis and atopic keratoconjunctivitis. It is primarily used to confirm the underlying allergen, particularly when establishing the indication for allergen immunotherapy (AIT). It can also be employed to monitor treatment effects such as e.g., AIT or pharmacotherapy. Although highly sensitive, the procedure of nasal ASA provocation remains a time-consuming procedure. While challenging in children, NPT provides clinically relevant additional diagnostic information on the causes of the allergic symptoms. Allergological diagnostic work-up also includes pulmonary assessment, particularly in patients with established asthma or symptoms suggestive of asthma. Both AAR and PNIF are applied as standard procedures for assessing the outcome of NPT in Germany. In individual cases, other rhinometric methods may also be used.Correspondence to:
Dr. Ulrike Förster-Ruhrmann, Department of Otorhinolaryngology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany, And Prof. Dr. Oliver Pfaar, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Baldingerstrasse, 35043 Marburg, Germany
Email: [email protected]
Intracranial metastasis of hepatocellular carcinoma with SMARCA4/BRG1 deficiency: A case report of a young patient easily misdiagnosed as atypical teratoid/rhabdoid tumor
Zhipeng Shen and Yingjie Zhang
Price
42.00 $
p. 0 - 6
Abstract
Zhipeng Shen and Yingjie Zhang
Department of Neurosurgery, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China
Hepatocellular carcinoma (HCC) is the most frequent histological subtype of primary liver cancer, accounting for 80 – 90% of all cases.SMARCA4/BRG1 (Brahma-related gene 1) has been reported as a tumor-promoting factor in HCC, with high expression being associated with advanced stage and poor prognosis. At present, SMARCA4/BRG1-deficient HCC is an extremely rare subtype, accounting for less than 1% of cases, and intracranial metastasis arising from this subtype has been scarcely documented. We report a rare case of a young patient presenting with intracerebral hemorrhage as the initial manifestation, for whom the initial pathological diagnosis was atypical teratoid/rhabdoid tumor, but eventually diagnosed with brain metastasis from SMARCA4/BRG1 deficient HCC. This case reminds us that in adult patients presenting with intracranial tumors exhibiting SMARCA4/BRG1 deficiency, a high index of suspicion for brain metastasis from HCC is warranted. SMARCA4/BRG1 deficiency typically endows tumors with increased invasiveness and suggests that this deficient state may reshape metastatic tropism, thereby conferring the ability to traverse the blood–brain barrier. These observations may provide a foundation for future studies investigating the molecular mechanisms underlying metastasis in this subset of tumors.Correspondence to:
Yingjie Zhang, MS, Department of Neurosurgery, The Second Hospital of Lanzhou University, Lanzhou, Gansu, China
Email: [email protected]
Neph
Education
Isolated primary glucosuria without SGLT2 mutation: A case report
Mercedes Galloway, Tarek Zaho, and Charles W. Heilig
Price
42.00 $
p. 0 - 4
Abstract
Mercedes Galloway1, Tarek Zaho2, and Charles W. Heilig1
1University of Florida College of Medicine, Jacksonville, FL, and 2Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA
Background: Primary renal glucosuria typically results from SLC5A2 mutations affecting SGLT2 and manifests as isolated urinary glucose excretion with normoglycemia. Rarely, sustained glucosuria occurs in the absence of known genetic mutations or systemic disease. Case presentation: A 63-year-old male with well-controlled stage 3 chronic kidney disease displayed lifelong glucosuria (urine glucose +50 to +100 mg/dL), beginning at age 18, with persistently normal HbA1c and no history of diabetes or systemic symptoms. Investigations showed isolated glucosuria on repeated urinalyses, minimal nonspecific amino acid changes, and negative targeted genetic testing for <i>SLC5A2</i>. He was diagnosed presumptively as primary renal glucosuria of unknown genetic etiology. The patient remains asymptomatic under conservative follow-up. Conclusion: This uncommon presentation of long-standing isolated glucosuria without SLC5A2 mutations highlights the need for broader genetic assessment, potentially whole-exome sequencing and enriched understanding of alternative renal glucose transport mechanisms.
Correspondence to:
Mercedes Galloway, MD, University of Florida College of Medicine, Jacksonville, FL, USA
Email: [email protected]
Original
Baloxavir marboxil versus oseltamivir phosphate: Efficacy, safety, and economics in patients with influenza
Yongli Gu and Daoli Jiang
Price
42.00 $
p. 0 - 11
Abstract
Yongli Gu1 and Daoli Jiang2,3
1Department of Pharmacy, the First People’s Hospital of Lianyungang, Lianyungang Jiangsu, 2Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, and 3Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou Jiangsu, China
Aims: To evaluate the efficacy, safety, and cost-effectiveness of baloxavir marboxil tablets versus oseltamivir phosphate capsules for treatment of influenza from the health-care system perspective. Materials and methods: Influenza patients were assigned to receive baloxavir marboxil (baloxavir group) or oseltamivir phosphate (oseltamivir group) and followed prospectively. Clinical outcomes, adverse events, and direct medical costs during treatment were collected. A cost-effectiveness analysis was performed from the health-care system perspective. Incremental cost-effectiveness ratios (ICERs) were calculated using 48-hour and 5-day recovery rates as effectiveness measures. Sensitivity analyses assessed drivers of results. Results: A total of 102 cases treated with baloxavir and 81 cases treated with oseltamivir were analyzed. There were no significant differences between groups in 5-day overall effectiveness (p = 0.111) or 5-day defervescence rate (p = 0.115). The baloxavir group showed significantly higher 48-hour effectiveness (p < 0.001), 48-hour recovery rate (p < 0.001), 48-hour defervescence rate (p < 0.001), and 5-day recovery rate (p = 0.023) compared with the oseltamivir group. Adverse event incidence was significantly lower in the baloxavir group (p < 0.001). Sensitivity analysis identified the antiviral agent as a significant driver of 48-hour effectiveness (p = 0.004), 48-hour recovery (p = 0.013), and 48-hour defervescence (p = 0.008). Results remained robust across analyses. Total outpatient and drug costs were significantly higher in the baloxavir group (both p < 0.001). Using 48-hour recovery and 5-day recovery as effectiveness endpoints, the ICERs for baloxavir versus oseltamivir were ¥92.23 and ¥794.29 per additional recovered patient, respectively. Conclusion: Baloxavir marboxil is superior to oseltamivir in efficacy, safety, and cost-effectiveness for influenza.
Correspondence to:
Dr. Daoli Jiang, Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou Jiangsu, 221006, China and Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou Jiangsu, 221004, China
Email: [email protected]
Original
Disproportionate reporting of seizures with histamine H1 receptor antagonists: The role of drug generation and brain H1 receptor occupancy assessed using the Japanese Adverse Drug Event Report database
Yu Masabe, Ryo Inose, Kanako Mizuno, and Yuichi Muraki
Price
42.00 $
p. 0 - 7
Abstract
Yu Masabe, Ryo Inose, Kanako Mizuno, and Yuichi Muraki
Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan
Background: Histamine H1 receptor antagonists are widely used as antiallergic agents. However, seizure reporting patterns across individual drugs, drug generation, and brain H1 receptor occupancy (H1RO)-based classification have not been comprehensively evaluated. Objective: To evaluate seizure signals for H1 receptor antagonists by drug generation and H1RO-based classification using the Japanese Adverse Drug Event Report (JADER) database. Materials and methods: Reports included in the JADER database from April 2004 to December 2024 were analyzed. Seizure signals for H1 receptor antagonists were evaluated using the reporting odds ratio (ROR). Analyses included all reports and a subgroup of patients under 10 years of age. Results: Overall, seizure signals were detected for selected individual H1 receptor antagonists in both generations, and the observed patterns were not consistently explained by drug generation or H1RO-based classification. As supporting findings, aggregated analyses showed signals for first-generation (ROR: 1.68, 95% CI: 1.46 – 1.93) and second-generation agents (ROR: 1.47, 95% CI: 1.34 – 1.61). In patients under 10 years of age, seizure signals were detected across both drug generations and different H1RO-based categories and were not consistently explained by either classification. Conclusion: These findings suggest that seizure signals differ across individual drugs, with similar patterns observed in children under 10 years of age. Individual drug characteristics and patient age may warrant consideration in drug selection rather than relying solely on drug generation or H1RO-based classification.
Correspondence to:
Ryo Inose, PhD, Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5, Misasagi-Nakauchicho, Yamashina-ku, Kyoto-shi, Kyoto 607-8414, Japan
Email: [email protected]
Original
Anti-EGFR antibody therapy and skin toxicity: Retrospective analysis and role of pharmacists in protocol-based pharmacotherapy management
Hajime Morita, Tomoya Sakurada, Ayami Hirano, Mari Makuuchi, Sayaka Kishimoto, Hiroko Minatogawa, Ikko Sakaue, Yu Sunakawa, Nobunori Sato, and Shingo Yamazaki
Price
42.00 $
p. 0 - 8
Abstract
Hajime Morita1,2, Tomoya Sakurada3, Ayami Hirano2, Mari Makuuchi2, Sayaka Kishimoto2, Hiroko Minatogawa2, Ikko Sakaue2, Yu Sunakawa4, Nobunori Sato5, and Shingo Yamazaki1
1Laboratory of Clinical Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, 2Department of Pharmacy, St. Marianna University Hospital, 3Laboratory of Community Medicine and Pharmacy, Faculty of Pharmaceutical Sciences, Department of Clinical Pharmacy, Josai International University, 4Department of Medical Oncology, St. Marianna University, and 5Department of Drug Informatics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
Objective: Anti-epidermal growth factor receptor (EGFR) antibodies are a therapy option for patients with advanced or recurrent colorectal cancer. However, these agents frequently cause skin toxicities, which compromise treatment continuity and negatively impact patient quality of life, and evidence regarding pharmacist-led interventions remains limited. We aimed to evaluate pharmacist-led pre-consultation interviews for patients receiving anti-EGFR antibodies by examining pharmacist-physician concordance in skin toxicity assessment, physician acceptance of pharmacist recommendations, and their contribution to dermatological toxicity management and multidisciplinary care. Materials and methods: We conducted a retrospective observational study in 95 patients with colorectal cancer who received anti-EGFR antibody therapy in an outpatient setting between November 2012 and November 2023. Data collected included i) implementation status of pharmacist-led pre-consultation interviews, ii) concordance rates with physicians in skin toxicity grading, iii) acceptance rates of pharmacist-initiated prescriptions, and iv) physician adoption of recommendations regarding dose modifications or dermatology referrals. Results: A total of 1,749 pharmacist-led pre-consultation interviews were conducted, achieving an implementation rate of 96.5%. Concordance rates between pharmacists and physicians for skin toxicity grading were approximately 98 – 99%, and the acceptance rate of pharmacist-initiated prescriptions exceeded 97%. Over 80% of the recommendations for dose adjustments and dermatology consultations were accepted. Conclusion: Pharmacist-led pre-consultation interviews facilitate accurate assessment and timely intervention for skin toxicities and serve as a practical tool to support physicians in treatment decision-making.
Correspondence to:
Shingo Yamazaki, PhD, Laboratory of Clinical Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8675, Japan
Email: [email protected]
Letter to the editor
A Spanish clinical perspective on national regularization of allergen immunotherapy products
Ruperto González-Pérez, Paloma Poza-Guedes, and Inmaculada Sánchez-Machín
Volume 10 (2026) p. 259 - 261
Abstract
Allergologie select, Vol. 10/2026 (259-261)
A Spanish clinical perspective on national regularization of allergen immunotherapy products
Ruperto González-Pérez1,2,3, Paloma Poza-Guedes1,2,3, and Inmaculada Sánchez-Machín1,3,4
1Allergy Department, 2Severe Asthma Unit, Allergy Department, Hospital Universitario de Canarias, 3Instituto de Investigación Sanitaria de Canarias (IISC), and 4Allergen Immunotherapy Unit, Allergy Department, Hospital Universitario de Canarias, Tenerife, Spain
Correspondence to:
Ruperto González-Pérez, MD, PhD, Allergy Department at the Hospital Universitario de Canarias, Ctra. La Cuesta-Taco s/n, 38320, Tenerife, Spain
Email: [email protected]
Case Report
Fixed drug eruption to propofol: Case series and clinical implications
Carole Guillet, Elisabeth Gössinger, Lukas Joerg6, Barbara Ballmer-Weber, Felicitas Bellutti-Enders, Valentina N.S. Hongler, Hazem A. Juratli, Karin Hartmann, Thierry Girard, Anne Leuppi-Taegtmeyer, Kathrin Scherer, Minaya Beigi, and Esther Helen Steveling-Klein
Volume 10 (2026) p. 262 - 267
Abstract
Allergologie select, Vol. 10/2026 (262-267)
Fixed drug eruption to propofol: Case series and clinical implications
Carole Guillet1,2,3,4,5, Elisabeth Gössinger1,2,3, Lukas Joerg6, Barbara Ballmer-Weber4,7, Felicitas Bellutti-Enders3,8, Valentina N.S. Hongler1,2,3, Hazem A. Juratli2,3,9,10, Karin Hartmann1,2,3,11, Thierry Girard2,3,12, Anne Leuppi-Taegtmeyer3,11,13,14, Kathrin Scherer3,15, Minaya Beigi1,2,3, and Esther Helen Steveling-Klein1,2,3,15
1Division of Allergy, Department of Dermatology, 2Department of Biomedicine, University Hospital Basel and University of Basel, Basel, 3Faculty of Medicine, University Basel, Basel, 4Department of Dermatology, University Hospital Zurich, Zurich, 5Faculty of Medicine, University of Zurich, Zurich, 6Division of Allergology and Clinical Immunology, Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, 7Division of Allergy, Clinic for Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, 8Allergy Unit, University Children’s Hospital Basel, Basel, 9Department of Dermatology, Universityhospital Basel, Basel, 10Department of Pathology, University Hospital Basel, Basel, 11Department of Clinical Research, University Hospital Basel and University of Basel, Basel, 12Clinic for Anaesthesia, Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel and University of Basel, Basel, 13Department of Patient Safety, Medical Directorate, University Hospital Basel, Basel, 14Clinical Pharmacology and Clinical Pharmacy Service, Cantonal Hospital Baselland, Liestal, and 15Dermatology and Allergology, Cantonal Hospital Aarau, Aarau, Switzerland
Background: Fixed drug eruption (FDE) is a type IV delayed hypersensitivity reaction characterized by recurrent lesions at the same site upon drug re-exposure. Propofol-induced FDE is extremely rare. Case Report: We report four cases of FDE following propofol administration, presenting with erythematous or bullous lesions at fixed sites, sometimes with mucosal involvement. Standard skin tests and lymphocyte transformation tests were frequently negative, particularly when performed outside previously affected areas. Diagnosis was confirmed by controlled intravenous provocation in one adult case. Histology supported the diagnosis when available. Discussion: FDE to propofol is likely under-recognized due to delayed onset of lesions. Diagnostic testing can be challenging, and controlled re-exposure may be required. Awareness of this rare reaction is important given propofol’s widespread use and limited alternative anaesthetic options. Reporting such cases improves recognition and guides safe management.Correspondence to:
Esther Steveling-Klein, MD, Division of Allergy, Department of Dermatology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
Email: [email protected]
Original
Dupilumab improves long-term asthma control in German patients with severe asthma: Real-world data
Andreas Renner, Slagjana Stoshikj, Eckard Hamelmann, Dirk Skowasch, Christian Schulz, Margret Jandl, Olaf Schmidt, Katrin Milger, Rainer Ehmann, Christian Taube, Stephanie Korn, Roland Buhl, Marco Idzko, and the German Asthma Net (GAN) study group
Volume 10 (2026) p. 268 - 279
Abstract
Allergologie select, Vol. 10/2026 (268-279)
Dupilumab improves long-term asthma control in German patients with severe asthma: Real-world data
Andreas Renner1,2, Slagjana Stoshikj1,2, Eckard Hamelmann3, Dirk Skowasch4, Christian Schulz5, Margret Jandl6, Olaf Schmidt7, Katrin Milger8,9, Rainer Ehmann10, Christian Taube11, Stephanie Korn12, Roland Buhl13, Marco Idzko1,2, and the German Asthma Net (GAN) study group
1Department of Pneumology, Medical University of Vienna, Vienna, Austria, 2Comprehensive Center for Chest Diseases, Medical University of Vienna, Vienna, Austria, 3Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld, 4Department of Internal Medicine II - Pneumology, University Hospital Bonn, Bonn, 5Department of Internal Medicine II, University Hospital Regensburg, Regensburg, 6Hamburger Institut für Therapieforschung GmbH, Hamburg, 7Pneumologische Gemeinschaftspraxis und Studienzentrum KPPK, Koblenz, Germany, 8Division of Respiratory Medicine, Lung Research Cluster, Department of Internal Medicine, Medical University of Graz, Graz, Austria, 9Department of Medicine V, Ludwig-Maximilians-University (LMU) of Munich, Comprehensive Pneumology Center (CPC-M) German Center for Lung Research (DZL), Munich, 10Ambulante Pneumologie mit Allergiezentrum, Stuttgart, 11Department of Pulmonary Medicine, University Hospital Essen – Ruhrlandklinik, Essen, 12Department of Pulmonary and Respiratory Critical Care Medicine, Thoraxklinik Heidelberg und IKF Pneumologie Mainz, and 13Pulmonary Department, Mainz University Hospital, Mainz, Germany
Background: Dupilumab has proven effective in severe asthma, but there is only sparse evidence on its impact on asthma control in a real-world setting. Materials and methods: All patients from the German Asthma Net (GAN) severe asthma registry who initiated dupilumab after inclusion into the registry were analyzed. Clinical effectiveness was evaluated in those with at least 2 follow-up visits, with a maximum followup time of 3 years. Results: A total of 481 patients with severe asthma initiated dupilumab. At baseline, median blood eosinophil count was 174 cells/μL (IQR 61.2 – 436); 184 (38.3%) were former smokers with median 9.6 pack-years (IQR 4.3 – 23.3). Clinical effectiveness was evaluated in 235 patients. The FEV1 increase from baseline was maintained over the whole study period (+300 mL at 4 months and 1 year, +200 mL at 2 and 3 years, all p < 0.0001). The frequency of exacerbations decreased, and the Asthma Control Test score increased from baseline clinically significantly at all timepoints (+4.3 at 4 months, +4.9 points at 1 year, +5.3 points at 2 years, and +4.6 points at 3 years, all p < 0.0001). Dupilumab was well tolerated; < 10% of patients reported adverse events or discontinued dupilumab treatment. The only adverse events recorded in more than 1 patient were conjunctivitis (4 patients), joint pain (3 patients), and flu-like symptoms (2 patients). Conclusion: In this large real-life study of dupilumab in patients with severe asthma dupilumab showed long-term clinical effectiveness for up to 3 years, with results consistent with prior randomized controlled trials.Correspondence to:
Andreas Renner, MD, Department of Pneumology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria
Email: [email protected]
Original
In-hospital sting challenge during venom immunotherapy has a high negative predictive value for subsequent sting reactions
Nicola Wagner, Eva Oppel, Jarmila Gloning, Annett Walker, Sophia Czell, and Franziska Ruëff
Volume 10 (2026) p. 280 - 284
Abstract
Allergologie select, Vol. 10/2026 (280-284)
In-hospital sting challenge during venom immunotherapy has a high negative predictive value for subsequent sting reactions
Nicola Wagner1, Eva Oppel2, Jarmila Gloning2, Annett Walker2, Sophia Czell2, and Franziska Ruëff2
1Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg (FAU), Erlangen, and 2Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany
Aims: Hymenoptera venom allergy is the most frequent elicitor of anaphylaxis in adults. Biomarkers predicting success of venom immunotherapy (VIT) are lacking. Only a re-sting may help to detect insufficiently protected individuals. The aim of the study was to investigate the prognostic value of a tolerated sting challenge with regard to future field stings. Materials and methods: A retrospective study included 585 consecutive patients of the AllergieZentrum Munich, Germany, who had tolerated a sting challenge test during VIT. Patients who were still on VIT were examined with a questionnaire evaluating the outcome of later field stings during ongoing VIT. Results: 439 of 585 patients (75%) could be evaluated. Of the 439 patients, 74/102 (75.2%) had tolerated a sting challenge with bee, 288/401 (74.1%) with yellow jacket, and 67/82 (81.7%) with both insects. In the follow-up time, 24.6% (108) had experienced at least 1 field sting. 104 of 108 patients (96.2%) had tolerated the sting without any reaction. Four patients (3.8%) reported systemic symptoms, 2 of whom experienced mild allergic immediate-type symptoms (1.9%). Conclusion: In patients on ongoing VIT a tolerated in-hospital sting provocation has a high negative predictive value (98.2%) in relation to the outcome of later field stings. The majority of these patients will subsequently not develop systemic reactions.Correspondence to:
PD Dr. med. habil. Nicola Wagner, MD, Department of Dermatology, Uniklinikum Erlangen, Ulmenweg 18, 91054 Erlangen, Germany
Email: [email protected]
Original
Species-specific outcomes in wasp sting challenges during venom immunotherapy and their respective follow-up
Eva Oppel, Felix V. Weber, Benjamin Kendziora, Bernhard G. Weiss, Paul Severin Wiggenhauser, Friedrich Ihler, Maya Bertlich, Nora Aszodi-Pump, Jennifer Lee Spiegel, Lars E. French, Saskia Freytag, and Mattis Bertlich
Volume 10 (2026) p. 285 - 295
Abstract
Allergologie select, Vol. 10/2026 (285-295)
Species-specific outcomes in wasp sting challenges during venom immunotherapy and their respective follow-up
Eva Oppel1, Felix V. Weber1, Benjamin Kendziora1,2,3, Bernhard G. Weiss4, Paul Severin Wiggenhauser5, Friedrich Ihler6, Maya Bertlich1,7, Nora Aszodi-Pump1, Jennifer Lee Spiegel4,8, Lars E. French1,2,9, Saskia Freytag10, and Mattis Bertlich1
1Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, 2Department of Dermatology, Thalkirchner Street Hospital, Munich Municipial Hospital Group, Munich, 3Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, 4Department of Otorhinolaryngology, Head and Neck Surgery, 5Division of Hand, Plastic and Aesthetic Surgery, LMU University Hospital, LMU Munich, Munich, 6Department of Otorhinolaryngology, Head and Neck Surgery, Greifswald University Medicine, Greifswald, 7Department of Dermatology, University Hospital Bonn, Bonn, 8Department of Otorhinolaryngology, University Hospital, Tübingen, Germany, 9Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA, and 10The Walter and Eliza Hall Institute of Medical Research and Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
Background: Insect venom allergy is a major cause of life-threatening anaphylaxis, with venom immunotherapy (VIT) being the gold standard for prevention. Sting challenges (SC) are used to assess immune tolerance and VIT efficacy, but factors influencing outcomes remain unclear. This study examined whether the stinging insect species affects SC outcomes during VIT and evaluated outcomes during long-term follow-up. Materials and methods: A retrospective analysis of 1,163 patients undergoing SC during wasp venom VIT was performed. The stinging species was entomologically confirmed. Associations between SC tolerance and species, skin prick test (SPT) results, venom-specific IgE levels, and treatment duration were analyzed using multivariable logistic regression adjusted for demographics. Follow-up assessed subsequent field stings and systemic reactions. Results: SCs were conducted with Vespula vulgaris (n = 479), Vespula germanica (n = 615), Dolichovespula media (n = 40), and Dolichovespula saxonica (n = 29). SC was tolerated without systemic reaction in 1,141 patients (98.1%). Vespula spp. were associated with a significantly higher likelihood of tolerance (odds ratio (OR) 7.69, 95% CI 2.66 – 20.43) compared with Dolichovespula spp. A decline in SPT positivity occurred after VIT, and conversion from positive to negative at 10 µg/mL showed a trend toward improved sting tolerance (OR 2.26, 95% CI 0.68 – 11.53). During follow-up (mean 53.2 ± 38.5 months), 167 patients experienced field stings; 6 developed systemic reactions, none of whom had been challenged with Dolichovespula spp. Conclusion: Species-specific differences influence sting challenge outcomes, suggesting incomplete cross-protection of Vespula VIT against Dolichovespula spp. Declining SPT reactivity may predict sting tolerance. SCs remain a reliable indicator of post-therapy protection against anaphylaxis.Correspondence to:
Prof. Dr. Mattis Bertlich, Department of Dermatology and Allergy, Ludwig-Maximilians University of Munich, Frauenlobstr. 9 – 11, 80337 Munich, Germany
Email: [email protected]
Review
Comparison between as-needed versus regular treatment for allergic rhinitis: Protocol for a systematic review
Catarina Ferreira, Vítor Henrique Duarte, Nicky Akbarian, Antonio Bognanni, Sara Gil-Mata, Ana Margarida Pereira, Manuel Marques-Cruz, Torsten Zuberbier, Holger J. Schünemann, João A. Fonseca, Jean Bousquet, Rafael José Vieira, and Bernardo Sousa-Pinto
Volume 10 (2026) p. 296 - 302
Abstract
Allergologie select, Vol. 10/2026 (296-302)
Comparison between as-needed versus regular treatment for allergic rhinitis: Protocol for a systematic review
Catarina Ferreira1,2, Vítor Henrique Duarte1,2,3, Nicky Akbarian4, Antonio Bognanni5, Sara Gil-Mata1,2, Ana Margarida Pereira1,2, Manuel Marques-Cruz1,2, Torsten Zuberbier6,7, Holger J. Schünemann5,7, João A. Fonseca1,2, Jean Bousquet6,7,8, Rafael José Vieira1,2, and Bernardo Sousa-Pinto1,2
1MEDCIDS – Department of Community Medicine, Information and Health Decision Sciences, 2CINTESIS@RISE – Health Research Network, 3Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal, 4Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, 5Clinical Epidemiology and Research Center (CERC), IRCCS Humanitas Research Hospital & Department of Biomedical Sciences, Humanitas University, Milan, Italy, 6Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 7Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany, and 8ARIA, Montpellier, France
Background: Allergic rhinitis (AR) impairs quality of life. While most trials assess regular regimen medication use, mobile-Health (mHealth) data suggest that most patients use treatments on an asneeded basis. Objectives: Protocol for a systematic review comparing as-needed versus regular AR treatment regimens regarding efficacy and safety. Materials and methods: We will conduct a systematic review and network meta-analysis (NMA) of randomized controlled trials involving patients of any age with perennial or seasonal AR. Oral and intranasal drugs will be compared in an as-needed regimen versus a regular regimen or placebo. Primary outcomes will be the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. Conclusion: This review will evaluate the efficacy and safety of two different strategies for AR management. The findings of this review will inform the Allergic Rhinitis and its Impact on Asthma (ARIA) 2024-2025 guidelines.Correspondence to:
Bernardo Sousa-Pinto, MEDCIDS – Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Rua Plácido Costa s/n, Paranhos, Porto, Portugal
Email: [email protected]
Editorial
Vorwort des Herausgebers
J. Piper
Jahrgang 13 (2026) p. 119 - 120
Abstract
Mikroskopie, Jahrgang 13, Nr. 3/2026, S. 119-120
Vorwort des Herausgebers
J. Piper
Originalarbeit
Ein Carl-Zeiss-„Tessovar“ mit Familienanschluss
E. Lüthje
Price
42.00 $
Jahrgang 13 (2026) p. 121 - 131
Abstract
Mikroskopie, Jahrgang 13, Nr. 3/2026, S. 121–131
Ein Carl-Zeiss-„Tessovar“ mit Familienanschluss
E. Lüthje
Im Jahr 2005 erhielt der Autor ein ausgemustertes Carl-Zeiss-„Tessovar“, das er für den Gebrauch an seiner Kamera umrüstete. Diese Zoom-Lupe, versehen mit einer Irisblende, konnte er sowohl im Labor am Senkrechtstativ und in waagerechter Installation als auch freihändig für Aufnahmen im Gelände verwenden. Bildbeispiele aus Botanik und Zoologie belegen die Anwendungsbreite und optische Qualität des Gerätes. Auf einschlägige Veröffentlichungen im „Mikrokosmos“ und der „Mikroskopie“ wird jeweils verwiesen. Im Alter von neun bzw. zehn Jahren erlernten die Enkel des Autors den Umgang mit dem „Tessovar“ und übernahmen dieses Gerät für eigene Erkundungen in der Welt der kleinen Dinge. So wurde der Generationswechsel vollzogen – die Jugend macht dort weiter, wo die „Alten“ aufgehört haben. Im vorliegenden Beitrag wird das Zeiss-„Tessovar“ vorgestellt. Verschiedene Makrofotografien des Autors und seiner Enkel veranschaulichen die Qualitäten und Einsatzmöglichkeiten dieses Gerätes.Correspondence to:
Dr. Erich Lüthje
Kruppallee 13
24146 Kiel
Email: [email protected]
Originalarbeit
Variable Anzahl der Expulsionsporen bei Ciliaten
G. Günther und K. Hausmann
Price
42.00 $
Jahrgang 13 (2026) p. 132 - 136
Abstract
Mikroskopie, Jahrgang 13, Nr. 3/2026, S. 132-136
Variable Anzahl der Expulsionsporen bei Ciliaten
G. Günther und K. Hausmann
Die Gründe der verschiedenen Bezeichnungen für kontraktile Vakuolen werden erläutert. Anzahl und Anordnung der Expulsionsporen pro kontraktile Vakuole werden am Beispiel von Paramecium und Didinium licht- und rasterelektronenmikroskopisch dokumentiert.Correspondence to:
Gerd Günther
Knittkuhler Straße 61
40629 Düsseldorf
und
Prof. a. D. Dr. Klaus Hausmann
ehemals Freie Universität Berlin
Rothenburgstr. 27b
12165 Berlin
Email: [email protected]; [email protected]; [email protected]
Originalarbeit
Zum nomenklatorischen Ursprung der Gattung Paramecium
K. Hausmann
Price
42.00 $
Jahrgang 13 (2026) p. 137 - 144
Abstract
Mikroskopie, Jahrgang 13, Nr. 3/2026, S. 137-144
Zum nomenklatorischen Ursprung der Gattung Paramecium
K. Hausmann
Der Ursprung der Gattungsbezeichnung Paramecium wird anhand historischer Bücher erforscht und im Lichte des Linnéschen binären Systems der Nomenklatur erklärt.Correspondence to:
Prof. a. D. Dr. Klaus Hausmann
ehemals Freie Universität Berlin
Rothenburgstraße 27b
12165 Berlin
Email: [email protected]
